Biblio
Between two kingdoms (CAR-T and hematopoietic stem cell transplantation). Transplant Cell Ther. 2022;28(8):413-414.
. Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2022.
Letter to the editor concerning " Single-institution experience of performing bloodless transplant in Jehovah's Witness patients" by Coltoff A, Aditya S, Solmaz A, and Steinberg A. (Hematol oncol stem cell ther 2019;12(1):44-9.). Hematol Oncol Stem Cell Ther. 2019.
. A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem-cell Transplant. Biol Blood Marrow Transplant. 2019.
Peripheral Immunotype Correlates with Minimal Residual Disease Status and is Modulated by Immunomodulatory Drugs (IMiDs) in Multiple Myeloma. Biol Blood Marrow Transplant. 2018.